Get the Stockscreener App
230.11
0.96%
-2.24
After Hours:
229.89
-0.22
-0.10%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $230.11, with a volume of 6.13M.
It is down -0.96% in the last 24 hours and up +2.99% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$232.35
Open:
$230.36
24h Volume:
6.13M
Relative Volume:
0.95
Market Cap:
$406.87B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
97.45
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
-0.85%
1M Performance:
+2.99%
6M Performance:
+8.26%
1Y Performance:
+9.19%
1-Day Range:
$226.80
$231.60
1-Week Range:
$226.80
$237.11
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
230.11 | 410.83B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
LLY
Lilly Eli Co
|
990.33 | 878.04B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
240.40 | 577.48B | 94.19B | 26.80B | 19.70B | 11.05 |
|
NVS
Novartis Ag Adr
|
160.12 | 307.23B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.22 | 306.31B | 58.80B | 10.24B | 8.98B | 3.2788 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Is AbbVie (ABBV) Still Priced Attractively After Its Strong Multi Year Share Price Run - Yahoo Finance Singapore
AbbVie (NYSE:ABBV) SVP David Ryan Purdue Sells 5,230 Shares - MarketBeat
AbbVie (ABBV): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
AbbVie (ABBV) Up 6.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance Singapore
These 3 Cash Flow Machines Provide Stability in Uncertain Markets - Investing.com
Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026? - TradingView
Edgar Lomax Co. VA Reduces Stock Position in AbbVie Inc. $ABBV - MarketBeat
Crossmark Global Holdings Inc. Raises Holdings in AbbVie Inc. $ABBV - MarketBeat
Berry Wealth Group LP Lowers Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie to invest $380 million in North Chicago campus to make next generation medicines - Daily Herald
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Chronic Idiopathic Constipation Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland - Barchart.com
Evercore ISI Adjusts AbbVie Price Target to $233 From $228, Maintains Outperform Rating - marketscreener.com
AbbVie (ABBV) Completes $7.75 Billion Notes Offering - GuruFocus
GW&K Investment Management LLC Sells 6,207 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Completes $8 Billion Senior Notes Financing Offering - TipRanks
Immunology, Obesity And Other Insights From The TD Cowen Healthcare Conference - Citeline News & Insights
US287YEG0 Bond Price and Chart — MUN:US287YEG0 - TradingView
AbbVie: Stabilizes Near $233 While Testing Resistance - Seeking Alpha
AbbVie: The Only Big Pharma Stock I'd Consider a Buy‑and‑Never‑Sell - The Globe and Mail
Uterine Fibroid Treatment Drugs Market Is Going to Boom Rapidly | - openPR.com
AbbVie stock price forecast: Stabilizes near $233 while testing resistance - Traders Union
ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS - AbbVie News Center
Neurogenic Detrusor Overactivity Market Is Going to Boom Rapidly | Astellas Pharma Inc., Allergan plc (AbbVie Inc.) - openPR.com
Griffith & Werner Inc. Invests $2.64 Million in AbbVie Inc. $ABBV - MarketBeat
Picton Mahoney Asset Management Has $25.14 Million Stake in AbbVie Inc. $ABBV - MarketBeat
How Positive Crohn’s Phase 3 Data for SKYRIZI Could Impact AbbVie (ABBV) Investors - simplywall.st
Dimensional Fund Advisors LP Has $2.06 Billion Position in AbbVie Inc. $ABBV - MarketBeat
Cresset Asset Management LLC Sells 15,199 Shares of AbbVie Inc. $ABBV - MarketBeat
Perry Siatis Sells 18,668 Shares of AbbVie Inc (ABBV) - GuruFocus
AbbVie (ABBV) EVP Roopal Thakkar reports tax-withholding share disposition - Stock Titan
AbbVie CEO reports tax-withholding share disposition | ABBV SEC FilingForm 4 - Stock Titan
AbbVie (NYSE: ABBV) EVP reports tax-withholding share disposition - Stock Titan
AbbVie (NYSE: ABBV) EVP Perry Siatis sells 18,668 shares - Stock Titan
AbbVie (ABBV) CFO uses 21,638 shares to cover tax withholding - Stock Titan
AbbVie (ABBV) SVP Purdue disposes 2,692 shares for tax withholding - Stock Titan
AbbVie (NYSE: ABBV) EVP uses shares to cover tax withholding - Stock Titan
PRESCRIPTION DRUGS—M.D. Tenn.: Court rejects AbbVie’s challenge to Tennessee contract pharmacy law - VitalLaw.com
US287YEJ4 Bond Price and Chart — FWB:US287YEJ4 - TradingView
AbbVie at TD Cowen: Strategic Insights and Growth Outlook - Investing.com
AbbVie to Present at the Leerink Partners Global Healthcare Conference - Investing News Network
Harvest Portfolios Group Reduces Stake in AbbVie - National Today
Victory Capital Management Inc. Buys 120,490 Shares of AbbVie Inc. $ABBV - MarketBeat
State Farm Mutual Automobile Insurance Co. Sells 69,551 Shares of AbbVie Inc. $ABBV - MarketBeat
Hear AbbVie management live at Leerink global healthcare conference - Stock Titan
Level Four Advisory Services LLC Trims Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Hits $31 Billion in Skyrizi and Rinvoq Sales - TIKR.com
Fisher Asset Management LLC Decreases Holdings in AbbVie Inc. $ABBV - MarketBeat
CI Investments Inc. Has $41.19 Million Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie to invest $380M in new North Chicago API manufacturing facilities - Chicago Construction News
AbbVie’s New Data And Approval Test Growth And Valuation Story - Yahoo Finance
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):